CAMBRIDGE, England & PARIS--(BUSINESS WIRE)--Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces a private equity placement financing of €3.1m.
New institutional investors in the Company include Alto Invest, who co-invested in the round alongside other new and existing Novacyt investors. Under the terms of the financing, investors will receive 744 004 of new Novacyt shares which were submitted to the Alternext Paris.
The share capital of Novacyt following the capital increase will amount to €418 048,13 representing 6 270 722 shares with a nominal value of 1/15th of a euro each.
Help employers find you! Check out all the jobs and post your resume.
New institutional investors in the Company include Alto Invest, who co-invested in the round alongside other new and existing Novacyt investors. Under the terms of the financing, investors will receive 744 004 of new Novacyt shares which were submitted to the Alternext Paris.
The share capital of Novacyt following the capital increase will amount to €418 048,13 representing 6 270 722 shares with a nominal value of 1/15th of a euro each.
Help employers find you! Check out all the jobs and post your resume.
